

Novartis Egypt launches preventive treatment for migraine

Novartis Egypt launched Erenumab, the first preventive treatment for episodic migraine and chronic migraine. Erenumab is a monoclonal antibody, a drug made from immune system cells that blocks the activity of certain proteins in the body. Clinical studies have proven that Erenumab reduced monthly migraine attacks by 75%. Additionally, more than a quarter of study participants no longer suffer from monthly headache attacks which has helped patients regain their ability to carry out daily activities normally.